{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Intestine+Cancer&page=9", "query": { "condition": "Small Intestine Cancer", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 627, "total_pages": 63, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Intestine+Cancer&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Intestine+Cancer&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T12:47:55.411Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03000179", "title": "Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2017-03-03", "completion_date": "2021-08-03", "has_results": true, "last_update_posted_date": "2022-04-14", "last_synced_at": "2026-10-20T12:47:55.411Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03000179" }, { "nct_id": "NCT06466187", "title": "A Study of SGN-MesoC2 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Ovarian Neoplasms", "Pancreatic Adenocarcinoma", "Colorectal Neoplasms", "Mesothelioma", "Other Solid Tumors", "Endometrial" ], "interventions": [ { "name": "PF-08052666", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2024-08-02", "completion_date": "2026-05-27", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-20T12:47:55.411Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Fairway, Kansas • Kansas City, Kansas + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06466187" }, { "nct_id": "NCT04579757", "title": "Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Solid Tumor", "Colorectal Cancer", "Neuroendocrine Tumors", "Small Cell Lung Cancer", "Gastric Cancer", "Soft Tissue Sarcoma", "Anaplastic Thyroid Cancer" ], "interventions": [ { "name": "Surufatinib and Tislelizumab _ Part 1", "type": "DRUG" }, { "name": "Surufatinib and Tislelizumab _ Part 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchmed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2021-03-05", "completion_date": "2024-08-27", "has_results": true, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-10-20T12:47:55.411Z", "location_count": 18, "location_summary": "Tucson, Arizona • Duarte, California • Denver, Colorado + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04579757" }, { "nct_id": "NCT06789172", "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours", "Sarcoma", "HNSCC", "Non Small Cell Lung Cancer", "NSCLC", "Colorectal Cancer (CRC)", "Myxofibrosarcoma (MFS)", "Solitary Fibrous Tumors", "Dedifferentiated Liposarcoma", "Undifferentiated Pleomorphic Sarcoma (UPS)", "Leiomyosarcoma", "Leiomyosarcoma (LMS)", "Gastric Cancer (GC)", "Gastric Cancer Adenocarcinoma Metastatic", "Gastric / Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "OKN4395", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Fasting", "type": "OTHER" }, { "name": "Fed", "type": "OTHER" }, { "name": "H2 Receptor Antagonist", "type": "DRUG" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "Epkin", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2025-01-23", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-20T12:47:55.411Z", "location_count": 3, "location_summary": "Beverly Hills, California • Santa Monica, California • Houston, Texas", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06789172" }, { "nct_id": "NCT07807956", "title": "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Biliary Tract Cancer", "Head and Neck Squamous Cell Carcinoma", "Ovarian Cancer" ], "interventions": [ { "name": "ABBV-253", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2026-09-14", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-20T12:47:55.411Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • Huntersville, North Carolina • Irving, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07807956" }, { "nct_id": "NCT02346955", "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Carcinoma (NSCLC)", "Melanoma", "Bladder Cancer", "Colorectal Cancer", "Gastric Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "CM-24 (MK-6018)", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (MK-3475)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Famewave Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2015-02", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2020-08-27", "last_synced_at": "2026-10-20T12:47:55.411Z", "location_count": 2, "location_summary": "Los Angeles, California • New Haven, Connecticut", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02346955" }, { "nct_id": "NCT01110135", "title": "Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Multiple Myeloma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "bendamustine hydrochloride", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "leukapheresis", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2010-08", "completion_date": null, "has_results": true, "last_update_posted_date": "2017-05-24", "last_synced_at": "2026-10-20T12:47:55.411Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01110135" }, { "nct_id": "NCT00003329", "title": "Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Lung Cancer", "Prostate Cancer" ], "interventions": [ { "name": "gene mapping", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "0 Years to 120 Years" }, "enrollment_count": 4000, "start_date": "1998-04-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-10-20T12:47:55.411Z", "location_count": 32, "location_summary": "Rancho Mirage, California • Fort Collins, Colorado • Boca Raton, Florida + 22 more", "locations": [ { "city": "Rancho Mirage", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003329" }, { "nct_id": "NCT04585750", "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Advanced Malignant Neoplasm", "Metastatic Cancer", "Metastatic Solid Tumor", "Lung Cancer", "Ovarian Cancer", "Endometrial Cancer", "Prostate Cancer", "Colorectal Cancer", "Breast Cancer", "Other Cancer", "Locally Advanced", "Head and Neck Cancer", "Gall Bladder Cancer", "Small Cell Lung Cancer", "Small Cell Lung Cancer ( SCLC )", "Small Cell Lung Carcinoma", "NSCLC", "NSCLC (Non-small Cell Lung Cancer)", "SCLC", "Non-Small Cell Lung Carcinoma", "Triple Negative Breast Cancer", "TNBC", "HER2+ Breast Cancer", "Non-Small Cell Lung Cancer", "ER/PR Positive Breast Cancer", "HER2- Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "ER/PR(+), Her2(-) Breast Cancer" ], "interventions": [ { "name": "rezatapopt", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PMV Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 300, "start_date": "2020-10-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-20T12:47:55.411Z", "location_count": 32, "location_summary": "Irvine, California • La Jolla, California • Los Angeles, California + 26 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04585750" }, { "nct_id": "NCT07503808", "title": "A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Squamous Cell Carcinoma", "High Grade Serous Ovarian Cancer", "Head and Neck Squamous Cell Carcinoma", "Colorectal Cancer", "Castration-resistant Prostate Cancer", "Non Small Cell Lung Cancer", "Endometrium Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "IDE034", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2026-02-24", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-20T12:47:55.411Z", "location_count": 15, "location_summary": "Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 10 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07503808" } ] }